Laboratory assay demonstrates exosomal glycoantigen detection in lung and breast cancer serum samples, indicating potential for noninvasive diagnosis.
Supplementary Figure S1. SPR assay detects exosomal TF-Ag-α for cancer diagnosis. Representative SPR curves for the detection of exosomal TF-Ag-α in serum samples from (a) a Stage II lung cancer patient using a biochip modified with IgG3 negative control antibodies; (b) a Stage 0 breast cancer patient using a biochip modified with IgG3 negative control antibodies, (c) a male normal control using a biochip modified with JAA-F11 antibodies, (d) a male normal control using a biochip modified with IgG3 negative control antibodies, (e) a female normal control using a biochip modified with JAA-F11 antibodies, and (f) a female normal control using a biochip modified with IgG3 negative control antibodies.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: